Short answer
Crinetics Pharmaceuticals, Inc. (CRNX) filed an 8-K current report with the SEC on July 6, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Vertex acquisition values Crinetics at $85.00 cash per share, making shareholders eligible for a definitive cash exit.
Crinetics Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Vertex acquisition values Crinetics at $85.00 cash per share, making shareholders eligible for a definitive cash exit
- Merger targeted for Q3 2026, subject to majority stockholder approval, antitrust clearances, and other closing conditions
- Unvested options and restricted stock units vest immediately before closing, with in-the-money awards converted to cash
- Vertex arranged $4.5B unsecured 364-day bridge financing, though closing is not contingent on financing
- $350,474,425 termination fee payable by Crinetics under specified circumstances, limiting competing-bid flexibility
Item 8.01 · Other Events
- Crinetics and Parent executed a merger agreement, initiating a proposed acquisition requiring stockholder and regulatory approval
- Transaction rationale centers on PALSONIFY, atumelnant, and broader pipeline potential in acromegaly and CAH
- Parent projects potential annual revenue above $5 billion and non-GAAP operating-income accretion in 2029
- Fully committed bridge financing supports Parent’s planned transaction funding
- Key risks include termination, competing offers, approval delays, litigation, integration costs, and failure to realize anticipated benefits
Item EX-99.1 · Exhibit EX-99.1
- Vertex agreed to acquire Crinetics for $85 per share in cash, valuing equity at approximately $10.0 billion
- Transaction expected to close in Q3 2026, subject to regulatory clearances and Crinetics shareholder approval
- Assets add more than $5 billion in potential peak annual revenue, led by PALSONIFY and Phase 3 atumelnant
- Vertex expects immediate revenue growth and non-GAAP operating-income accretion beginning in 2029
- Vertex will fund the purchase with cash and debt, including $4.5 billion of committed bridge financing
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Crinetics Pharmaceuticals, Inc. 8-K filings
Get the next CRNX 8-K as it lands
Follow CRNX for push alerts, or ask the research agent what this filing means.